Dynamics of tumor-specific cfDNA in response to therapy in multiple myeloma patients

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

VRÁBEL Dávid SEDLARIKOVA Lenka BESSE Lenka ŘÍHOVÁ Lucie BEZDEKOVA Renata ALMÁŠI Martina KUBACZKOVÁ Veronika BROŽOVÁ Lucie JARKOVSKÝ Jiří PLONKOVA Hana JELINEK Tomas SANDECKA Viera STORK Martin POUR Luděk ŠEVČÍKOVÁ Sabina HAJEK Roman

Year of publication 2020
Type Article in Periodical
Magazine / Source European Journal of Haematology
MU Faculty or unit

Faculty of Medicine

Citation
Web https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ejh.13358
Doi http://dx.doi.org/10.1111/ejh.13358
Keywords cell-free DNA; liquid biopsy; multiple myeloma; qPCR
Description Objectives Progress in multiple myeloma treatment allows patients to achieve deeper responses, for which the assessment of minimal residual disease (MRD) is critical. Typically, bone marrow samples are used for this purpose; however, this approach is site-limited. Liquid biopsy represents a minimally invasive and more comprehensive technique that is not site-limited, but equally challenging. Methods While majority of current data comes from short-term studies, we present a long-term study on blood-based MRD monitoring using tumor-specific cell-free DNA detection by ASO-qPCR. One hundred and twelve patients were enrolled into the study, but long-term sampling and analysis were feasible only in 45 patients. Results We found a significant correlation of quantity of tumor-specific cell-free DNA levels with clinically meaningful events [induction therapy (P = .004); ASCT (P = .012)]. Moreover, length of cfDNA fragments is associated with better treatment response of patients. Conclusions These results support the concept of tumor-specific cell-free DNA as a prognostic marker.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.